CD274 and non-small cell lung carcinoma: However, in the phase III IMpower010 study,56 anti-PD-L1 atezolizumab adjuvant treatment was found to improve the progression-free survival (PFS) (HR 0.79) and DFS (HR 0.66) of patients with resectable non-small cell lung cancer (NSCLC).